The AD and control clusters are distinguishable from each other by molecular measures reflecting the transcriptional changes associated with AD diagnoses (higher in cluster 3), as well as amyloid β plaque density and ApoE4 allele counts (higher in cluster 6), but not clinical dementia, even though patients in cluster 3 are younger than in cluster 6. Here, APOE is linked to Alzheimer disease.